

Blood trematodes: Schistosomiasis in Central Nervous System

by Yuliana

Submission date: 04-Nov-2025 09:05AM (UTC+0700)

Submission ID: 2400879299

File name: artikel-ra-653-for-review.docx (6.92M)

Word count: 4040

Character count: 25389

REVIEW ARTICLE

Blood trematodes: Schistosomiasis in Central Nervous System

Trematoda Darah: Schistosomiasis pada Sistem Saraf Pusat

ABSTRACT

Schistosomiasis (bilharzia) is an acute and chronic disease caused by blood trematode worms of the genus *Schistosoma*. There are five species of *Schistosoma* (*S. japonicum*, *S. mansoni*, *S. intercalatum*, *S. Mekongi*, dan *S. haematobium*) known to infect humans that are distributed across a wide geographic range. Severe clinical symptoms of schistosomiasis infection on the central nervous system (CNS) are caused by the deposition of eggs when adult worms migrate abnormally to the brain or spinal cord. As a result, radiculopathy, myelopathy, increased intracranial pressure, and clinical sequelae occur. Each species shows different tendencies for atopic infections and clinical symptoms. The most common neurological symptom caused by *Schistosoma mansoni* or *S. haematobium* infections is myelopathy, and severe encephalitis is most likely caused by *S. japonicum* infections. The symptoms of encephalopathy can manifest as headache, vision disturbances, delirium, convulsions, motor limitations, and ataxia. Spinal abnormalities may lead to backache, lower limb radiating discomfort, muscular frailty, the lapse of sensation, and urinary impairment. Histopathological analysis showing granulomas and *Schistosoma* eggs is necessary for a definitive diagnosis. Current management involves surgical procedures, steroids, and schistosomicide drugs. Corticosteroids are administered in the acute stage, and praziquantel is given after the female worm begins to lay eggs. If medical intervention fails to relieve compression or medullary degeneration, surgery should be postponed in certain cases. The earlier a diagnosis is identified, and proper therapy begins, the better the patient's outcome.

Keywords: tropical disease; *schistosoma*; schistosomiasis; brain; spine

ABSTRAK

Schistosomiasis adalah suatu penyakit akut sekaligus kronis yang disebabkan oleh cacing trematoda darah dari genus *Schistosoma*. Terdapat lima spesies *Schistosoma* (*S. japonicum*, *S. mansoni*, *S. intercalatum*, *S. Mekongi*, dan *S. haematobium*) yang diketahui menginfeksi manusia dan tersebar di rentang geografis yang luas. Gejala klinis berat akibat infeksi schistosomiasis pada sistem saraf pusat (SSP) disebabkan oleh deposit telur ketika cacing dewasa bermigrasi secara abnormal ke otak atau sumsum tulang belakang. Akibatnya, terjadi radikulopati, mielopati, peningkatan tekanan intrakranial, dan sekuel klinis. Setiap spesies menunjukkan kecenderungan infeksi atopik dan gejala klinis yang berbeda. Gejala neurologis paling umum yang disebabkan oleh infeksi *Schistosoma mansoni* (*S. mansoni*) atau *S. haematobium* adalah mielopati, sementara ensefalitis berat lebih sering terjadi pada infeksi *S. japonicum*. Gejala ensefalopati dapat berupa sakit kepala, gangguan penglihatan, delirium, kejang, keterbatasan motorik, dan ataksia. Kelainan tulang belakang dapat menyebabkan nyeri punggung, rasa tidak nyaman yang menjalar ke tungkai bawah, kelemahan otot, hilangnya sensasi, dan gangguan berkemih. Analisis histopatologi yang menunjukkan granuloma dan telur *Schistosoma* diperlukan untuk diagnosis pasti. Penanganan saat ini mencakup prosedur bedah, steroid, dan obat schistosomisida; kortikosteroid diberikan pada tahap akut, dan praziquantel digunakan setelah cacing betina mulai bertelur. Jika intervensi

medis gagal meredakan kompresi atau degenerasi medula, pembedahan dapat dipertimbangkan dalam kasus tertentu. Semakin dini diagnosis ditegakkan dan terapi yang tepat dimulai, semakin baik prognosis pasien.

Kata kunci: penyakit tropis; *Schistosoma*; schistosomiasis; otak; tulang belakang

INTRODUCTION

The COVID-19 pandemic and efforts to control it in 2021 resulted in a reduced focus of governments and healthcare providers, particularly on the availability of interventions and treatments for neglected tropical diseases (NTDs), including schistosomiasis.¹⁻³ Schistosomiasis (bilharzia) is an acute and chronic disease caused by blood trematode worms of the genus *Schistosoma*.⁴ Schistosomiasis is prevalent in tropical and subtropical regions, especially in poor communities that do not have access to safe drinking water and adequate sanitation.⁵ World Health Organization (WHO) reports that schistosomiasis in all its forms has been transmitted in 78 countries, of which 51 are endemic countries requiring preventive chemotherapy (Figure 1).⁶



Figure 1. Map of the geographical distribution of schistosomiasis.

¹⁷
Source: <https://www.who.int/data/gho/data/themes/topics/schistosomiasis>

It is estimated that around 251.4 million people required preventive treatment for schistosomiasis in 2021 and more than 75 million people have received treatment.⁶ There are five species of *Schistosoma* known to infect humans that are distributed across a wide geographic range.^{6,7} Infections with *S. japonicum*, *S. mansoni*, *S. intercalatum*, and *S. mekongi* have been linked to protracted intestinal and liver fibrosis, while chronic infections of *S. haematobium* are prone to the formation of fibrosis, narrowing, and calcified bladder.^{8,9} Ectopic

eggs of the species *Schistosoma* migrate to various organs and give rise to clinical manifestations based on the affected organs, such as the skin, brain, muscles, eyes, adrenal glands, and genitourinary system. Granulomas can form in the fallopian tubes, ovaries, and uterus.⁹

The term "neuro-schistosomiasis" refers to schistosomiasis of brain tissue, which is the most severe clinical form of *Schistosoma* infection and can arise symptomatically or asymptotically due to schistosomes.¹⁰ Neuro-schistosomiasis cases have been found in soldiers and workers serving in schistosomiasis endemic areas, as well as in tourists who rarely visit these areas.¹¹ *Schistosoma japonicum*, *S. mansoni*, *S. haematobium* are common species that cause neuro-schistosomiasis. Infection of *S. japonicum* typically leads to acute encephalitis involving the cerebral cortex, basal ganglia, subcortical white matter, or inner capsule.¹² Infections of *S. mansoni* or *S. haematobium* can cause neurological manifestations, particularly myelopathy (acute transverse myelitis and subacute myeloradiculopathy) linked to necrotic inflammation in the lumbo-sacral area.^{13,14}

METHODS

A literature search was conducted between September and October 2023 using the keywords "schistosomiasis" OR "*Schistosoma* " OR "infection AND brain AND *Schistosoma* " OR "schistosomiasis AND brain" OR "schistosomiasis AND nervous system AND central" OR "schistosomiasis AND spinal" OR "schistosomiasis AND bone and back". Literature is gathered from the electronic databases PubMed, Scopus, and Google Scholar, and the bibliographies of relevant publications. The search was limited to freely accessible full-text articles in English, but no systematic methodology was applied to the search and selection process.

RESULTS

Life Cycle

Schistosoma has a complex life cycle (Figure 2), involving freshwater snails as intermediate hosts and higher vertebrates or mammals as definitive hosts, where *Schistosoma* lives in the bloodstream of mammals.¹⁵ Male and female *Schistosoma* worms mate, with the female residing in the male's ventral gynacophoric canal. Female *S. mansoni* lays 100–300 eggs daily, *S. haematobium* lays 20–200, and *S. japonicum* lays 500–3,500. Egg shape and location help differentiate species, as they accumulate in the target organ's capillaries.¹⁶ Highly antigenic eggs migrate through the intestinal wall or bladder and are excreted in feces or urine.^{16,17}

Once expelled into freshwater, eggs hatch into miracidia within ten days, which infect specific snail intermediate hosts, transforming into sporocysts and later into cercariae. The cercariae, capable of free-swimming for up to 72 hours, must find and penetrate a definitive mammalian host within 12–24 hours to continue the life cycle.^{16,17} Each *Schistosoma* species has a distinct snail host in endemic regions; for example, *Oncomelania hupensis* hosts *S. japonicum*, while *Biomphalaria* species host *S. mansoni*. Cercariae penetrates intact skin using

suckers and proteolytic enzymes, sheds their tails, and migrate via the lymphatic system to the lungs, where they develop immune-resistant schistosomula. These schistosomula travel to the liver's portal vessels, mature into adult worms, and form pairs before migrating to their target organs, completing the life cycle.¹⁸ This complex parasitic process underpins the persistence of schistosomiasis in endemic regions.




Figure 2. Life cycle of the worm *Schistosoma* spp.

Pathogenesis

After the worms develop into adults, they reproduce, and produce eggs. *Schistosoma* can enter the central nervous system. After maturation and reproduction, *Schistosoma* can invade the central nervous system (CNS). Eggs must enter Batson's epidural venous plexus, linking the portal vein and vena cava systems to the spinal cord and cerebral veins, to induce CNS symptoms. Through this route, mature worms may deposit eggs near the CNS or embolize large numbers from mesenteric vessels. The smaller, spherical eggs of *S. japonicum* can reach the CNS, while the larger eggs of *S. mansoni* and *S. haematobium* are typically confined to the lower vertebral cord.^{13,16,19} In chronic hepatosplenic and cardiopulmonary schistosomiasis, venous or arterial invasion mechanisms can result in CNS implication without symptoms.^{13,20} The rare detachment of eggs and the lack of a peri-ovular inflammatory response associated with severe chronic infections result in an absence of symptoms.²⁰

Schistosomiasis pathology primarily arises from the intense inflammatory response to trapped eggs, not the worms themselves. Eggs contain miracidia, which can mature into adults within 5–20 days. Chronic disease is driven by host immune reactions and granulomatous responses to antigens, particularly glycoproteins, secreted by miracidia. Granulomas predominantly form where eggs accumulate: *S. mansoni* and *S. japonicum* in the intestines and liver, and *S. haematobium* in the genitourinary tract.^{19,21} Granulomas may form in tissues such

as the brain, muscles, skin, lungs, and adrenal glands. Perioval granulomas consist of fibroblasts, eosinophils, and plasma cells, with necrotic centers containing egg clusters surrounded by giant cells, lymphocytes, and epithelioid cells. While single eggs are reabsorbed, tissue damage can lead to fibrosis. Chronic infections result in calcified eggs and excess extracellular matrix deposition due to granulomatous inflammation. Collagen deposition, crosslinking, contraction, and reabsorption are dynamically regulated by immune responses.²¹

Clinical Manifestations

Schistosomiasis of the cerebral

Brain involvement in schistosomiasis is more frequent with *S. japonicum* infections (4–28%) than with other *Schistosoma* species. The primary neurological manifestations are diffuse encephalopathy and seizures. The smaller eggs of *S. japonicum* have a higher likelihood of penetrating the brain.¹⁹ Granulomatous lesions and increased intracranial pressure in the subcortical white matter, cortex, internal capsule, or basal ganglia commonly manifest as neurological disturbances, including fever, headache, nystagmus, speech difficulties, and motor weakness. One possible outcome of high pressure in the brain is papilledema. Neurological symptoms typical of cerebral complications due to infection *S. japonicum* are seizures, both focal and generalized. Brain granulomas caused by *Schistosoma* can trigger partial motor seizures and secondary generalized tonic-clonic seizures. In the absence of systemic infection, partial motor seizures may serve as an early and sole indicator of neuro-schistosomiasis.²² Brain infection-related complications of *S. haematobium* or *S. mansoni* typically affect the brain cortex, cerebellum, and leptomeninges.²³

Pseudo-tumoral encephalic schistosomiasis (PES), primarily caused by *S. japonicum*, occurs predominantly in individuals aged 10–40 from endemic regions without other schistosomiasis manifestations. While all brain lobes may be affected, the cerebellar, occipital, and frontal lobes are most involved. PES may also present extracerebral lesions on the dura mater's inner surface. Neurological symptoms result from slow-growing brain lesions, edema, and mass effects, leading to increased intracranial pressure, intracranial hypertension, or hydrocephalus. Common symptoms include headaches, motor and sensory disorders, visual disturbances, mental status changes, vertigo, speech disorders, vomiting, and ataxia, with cerebral nerve paralysis and meningeal signs being rare. Diagnosis relies on identifying eggs or granulomas via biopsy, as other diagnostic methods are nonspecific.²⁴

Schistosomiasis of the spine

The predominant form of neuro-schistosomiasis, spinal cord schistosomiasis (SCS), is primarily caused by *Schistosoma mansoni* and typically occurs without other infection symptoms.^{10,13} However, previous reports mentioned that SCS occurred during acute toxic schistosomiasis (ATS), immediately afterwards or simultaneously with hepatosplenic types. SCS is more common in children, adolescents, and young adults than in the elderly. The clinical manifestations of SCS are classified in three forms: [1]

Medullary form, mainly involving the spinal cord; [2] Myeloradicular, involving the spinal cord and nerve roots; [3] Conus-cauda equina syndrome, dominant involving the conus or cauda equina. Medullary schistosomiasis typically presents with symmetrical sensorimotor anomalies, rapid progression, and severe weakness. In contrast, conus-cauda equina syndrome progresses more slowly, with asymmetrical sensorimotor changes and milder weakness. The myeloradicular type, the most common form, presents intermediate features and is primarily caused by *S. mansoni* and *S. haematobium*.²⁵

Other symptoms in neuro-schistosomiasis

Immunocompromised individuals with schistosomiasis may develop cerebral vasculitis, mediated by eosinophil-induced toxicity. During the acute stage, schistosomula have not matured, and eggs are undetectable, as *Schistosoma* begins egg production 1–2 months post-infection. Severe cases, such as *S. mansoni* infestations, can result in hyper-eosinophilic syndrome, leading to ischemic infarctions and chronic endomyocardial fibrosis.²⁶ Granulomatous inflammation around *Schistosoma* eggs may cause cerebral arterial necrosis, resulting in subacute hematomas, cerebellar hematomas, or subarachnoid hemorrhage. These neurological complications highlight the severe impact of schistosomiasis on the central nervous system.²⁷

Diagnosis

Conventional microscopic detection

Parasitological detection of *Schistosoma* eggs in urine or feces is critical for diagnosing active schistosomiasis, with the Kato-Katz method and miracidia hatching technique (MHT) considered the "gold standard," particularly in endemic areas. The Kato-Katz method, using 25–50 mg of stool, is valued for its simplicity, cost-effectiveness, and ability to identify species and estimate worm burden. However, it is less effective in detecting low-intensity infections, especially in non-endemic or low-prevalence areas.²⁸

The Helmintex test, employing paramagnetic beads, offers higher sensitivity than Kato-Katz but requires further evaluation for cost-effectiveness and field applicability. For superior diagnostic accuracy, rectal biopsy with ovogram, which has 95–100% sensitivity, is often preferred for diagnosing active schistosomiasis.^{29,30}

Radiology feature of neuro-schistosomiasis

Diagnosis of neuro-schistosomiasis by neuroimaging using computerized tomography scan (CT) and magnetic resonance imaging (MRI) can provide effective results. In addition, CT and MRI can evaluate the severity of the disease process and its complications in the target organ.³¹ CT images in neuro-schistosomiasis are associated with inflammatory reactions and granuloma formation due to egg deposition in the brain and spinal cord, generally showing mass lesions with hyperdense lesions surrounded by edematous shadows or calcification of hypodense with varying contrast enhancements. Granulomatous lesions are also associated with secondary bleeding.³²

MRI is effective in diagnosing cerebral and spinal schistosomiasis, revealing masses with scattered or clustered nodular "mud-like" enhancements in cortical or subcortical areas. Spinal schistosomiasis typically appears as lesions with spinal edema, conus medullaris, cauda equina involvement, and irregular thickening of the cauda equina nerve roots. MRI also detects spinal cord compression.^{24,32} The MRI images of neuroschistosomiasis usually show enlargement of the spinal cord, especially in the ventral area of the spinal cord, due to the formation of intramedullary *Schistosoma* granulomas. These granulomas may emerge as unevenly nodular multiple lesions resembling beaded strands, diverse highly intense lesions with ill-defined boundaries, or moderate extensions of distally located medulla that are iso-intense compared to the medulla oblongata.¹⁴ Spinal cord atrophy can be found in longstanding cases.²²

Immunology detection

Immunological methods for detecting *Schistosoma* antibodies are highly sensitive, cost-effective, and simple, making them useful for early screening and surveillance in endemic areas. These methods, including ELISA, IHA, and immune fluorescence, detect IgG, IgM, or IgE against soluble egg or adult worm antigens. While serology is beneficial for diagnosing travelers and patients without eggs, such as those with Katayama syndrome, it is less specific compared to fecal screening due to cross-reactivity with other worms.^{28,30}

Molecular technique

Nucleic acid detection, particularly PCR, offers superior sensitivity and specificity for diagnosing schistosomiasis, effectively detecting *Schistosoma* DNA in various samples, including feces, urine, blood, and environmental specimens. Blood-based PCR is promising for acute schistosomiasis, while real-time PCR can estimate *S. mansoni* infection burden. However, these methods require costly infrastructure and rigorous validation for broader application in control programs.^{29,33,34}

Treatment

Praziquantel

A pyrazinoisoquinoline derivative, praziquantel is a secure schistosomicidal, very potent, and effective oral drug against every adult worm of *Schistosoma* species.³⁴ Praziquantel has been widely used since its invention in the middle of the last century because of its safety and potency. Due to currently no vaccine for immunization, praziquantel has become the backbone of schistosomicidal. The precise mode of action of praziquantel remains undetermined, and while the calcium-ions pathway of *Schistosoma* was recently proposed as a molecular target, the data is yet inconclusive.³⁵

Artemether

Artemether and artesunate, derived from *Artemisia annua*, were first identified as anti-schistosomal agents in the 1980s, particularly against *S. japonicum*. These artemisinin

derivatives, originally used for malaria, are effective against juvenile *Schistosoma* within the first three weeks of infection. Administering artemether biweekly effectively targets and eliminates schistosomula in humans and animals.³⁵

Corticosteroid

For encephalopathy schistosomiasis, prednisone (1.5–2.0 mg/kg daily for three weeks) combined with praziquantel is recommended during the egg-laying period to reduce CNS granulomatous inflammation, though no randomized trials have confirmed corticosteroid effects on the spinal cord. Praziquantel is not advised during acute infection due to its inability to target immature schistosomula (3–21 days). Corticosteroids remain the preferred treatment, while the potential use of artemether, alone or with corticosteroids, for neurologic complications requires further study.^{25,36,37}

Disease Prevention

Research on schistosomiasis vaccines, including *S. mansoni* smFABP and DNA-based approaches, shows a promising progress. While praziquantel lacks preventive effects, artemether offers prophylactic potential when taken biweekly, effectively targeting all major *Schistosoma* species.⁸ In addition to vaccination and alternative medicine, there are several important factors in efforts to control schistosomiasis, especially in endemic areas⁶: [1]. Provide population-based preventive chemotherapy; [2]. Ensure a safe water supply; [3]. Health education for improved water sanitation; [4]. Avoiding urine or stool contaminated with schistosome is a prerequisite; [5]. Eradicating snails reduces worm transmission and adds further control. Visitors to endemic regions should be aware of potential exposure to freshwater larvae. Prompt treatment is recommended upon clinical suspicion or confirmed diagnosis of schistosomiasis to reduce disease burden. Topical lotions containing N, N-diethyl-m-toluamide effectively kill *Schistosoma* cercariae with minimal risk to humans.³⁸

CONCLUSION

Neuro-schistosomiasis with symptoms of *Schistosoma* involvement in the CNS is a serious condition. Despite increasing reports of the disease in endemic areas and among tourists, it remains underdiagnosed. *Schistosoma* infestations can result in harm to the central nervous system and spinal cord. The stage of infection and the clinical form affect the etiology, clinical picture and prognosis. Reducing irreversible neurological consequences and improving clinical outcomes requires immediate identification and intervention. To effectively treat neuro-schistosomiasis, the best treatment is to combine targeted anti-*Schistosoma* treatment with rapid surgical debridement. Early diagnosis accompanied by prompt and appropriate treatment will improve the patient's prognosis.

ACKNOWLEDGEMENT

None.

AUTHORS CONTRIBUTION

All authors contributed to this ¹³article.

FUNDING

None.

CONFLICT OF INTEREST

All authors declare that they have no conflict of interest concerning the submitted manuscript.

REFERENCES

1. Filip R, Gheorghita Puscaselu R, Anchidin-Norocel L, Dimian M, Savage WK. Global Challenges to Public Health Care Systems during the COVID-19 Pandemic: A Review of Pandemic Measures and Problems. *J Pers Med*. 2022;12(1295):1–22.
2. Hrynick TA, Ripoll Lorenzo S, Carter SE. COVID-19 response: Mitigating negative impacts on other areas of health. *BMJ Glob Health*. 2021 Apr 15;6(4):1–11.
3. Kokaliaris C, Garba A, Matuska M, Bronzan RN, Colley DG, Dorkenoo AM, et al. Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study. *Lancet Infect Dis*. 2022 Jan 1;22(1):136–49.
4. Abdel-Naser MB, Altenburg A, Zouboulis CC, Wollina U. Schistosomiasis (bilharziasis) and male infertility. *Andrologia*. 2019 Feb 1;51(1).
5. Phillips AE, Ower AK, Mekete K, Liyew EF, Maddren R, Belay H, et al. Association between water, sanitation, and hygiene access and the prevalence of soil-transmitted helminth and schistosome infections in Wolayita, Ethiopia. *Parasit Vectors*. 2022;15(1).
6. World Health Organization. WHO guideline on control and elimination of human schistosomiasis [Report] [Internet]. 2022 [cited 2023 Dec 21]. Available from: <https://iris.who.int/bitstream/handle/10665/351856/9789240041608-eng.pdf?sequence=1>
7. Rey O, Webster BL, Huyse T, Rollinson D, Van den Broeck F, Kincaid-Smith J, et al. Population genetics of African *Schistosoma* species. Vol. 89, *Infection, Genetics and Evolution*. Elsevier B.V.; 2021.
8. McManus DP, Bergquist R, Cai P, Ranasinghe S, Tebeje BM, You H. Schistosomiasis—from immunopathology to vaccines. Vol. 42, *Seminars in Immunopathology*. Springer; 2020. p. 355–71.
9. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN. Schistosomiasis. *Nat Rev Dis Primers*. 2018 Dec 1;4(1).

10. Carbonell C, Rodríguez-alonso B, López-bernús A, Almeida H, Galindo-pérez I, Velasco-tirado V, et al. Clinical spectrum of schistosomiasis: An update. *J Clin Med*. 2021;10(23).
11. Aula OP, McManus DP, Jones MK, Gordon CA. Schistosomiasis with a focus on Africa. *Trop Med Infect Dis*. 2021;6(3).
12. Garcia HH, Nath A, Del Brutto OH. Parasitic Infections of the Nervous System. *Semin Neurol*. 2019;39(3):358–68.
13. Dastoli PA, Leite AL, da Costa MDS, Nicácio JM, Pinho RS, Ferrarini MAG, et al. Medullary neuroschistosomiasis in adolescence: case report and literature review. Vol. 37, *Child's Nervous System*. Springer Science and Business Media Deutschland GmbH; 2021. p. 2735–41.
14. Majmundar N, Patel PD, Dodson V, Tran A, Goldstein I, Assina R. Parasitic infections of the spine: Case series and review of the literature. *Neurosurg Focus*. 2019;46(1).
15. Bu L, Zhong D, Lu L, Loker ES, Yan G, Zhang SM. Compatibility between snails and schistosomes: insights from new genetic resources, comparative genomics, and genetic mapping. *Commun Biol*. 2022;5(1).
16. Nation CS, Da'dara AA, Marchant JK, Skelly PJ. Schistosome migration in the definitive host. Vol. 14, *PLoS Neglected Tropical Diseases*. Public Library of Science; 2020. p. 1–12.
17. Candido RRF, Favero V, Duke M, Karl S, Gutiérrez L, Woodward RC, et al. The affinity of magnetic microspheres for *Schistosoma* eggs. *Int J Parasitol*. 2015 Jan 1;45(1):43–50.
18. Deslyper G, Doherty DG, Carolan JC, Holland CV. The role of the liver in the migration of parasites of global significance. Vol. 12, *Parasites and Vectors*. BioMed Central Ltd.; 2019.
19. Costain AH, MacDonald AS, Smits HH. Schistosome Egg Migration: Mechanisms, Pathogenesis and Host Immune Responses. Vol. 9, *Frontiers in Immunology*. Frontiers Media S.A.; 2018.
20. Macháček T, Leontovych R, Šmídová B, Majer M, Vondráček O, Vojtěchová I, et al. Mechanisms of the host immune response and helminth-induced pathology during *Trichobilharzia regenti* (Schistosomatidae) neuroinvasion in mice. *PLoS Pathog*. 2022;18(2).
21. Schwartz C, Fallon PG. *Schistosoma* “Eggs-iting” the host: Granuloma formation and egg excretion. *Front Immunol*. 2018;9.
22. Zaqout A, Abid F Ben, Murshed K, Al-Bozom I, Al-Rumaihi G, Al Soub H, et al. Cerebral schistosomiasis: Case series from Qatar. *International Journal of Infectious Diseases*. 2019 Sep 1;86:167–70.

23. Rose MF, Zimmerman EE, Hsu L, Golby AJ, Saleh E, Folkerth RD, et al. Atypical presentation of cerebral schistosomiasis four years after exposure to *Schistosoma mansoni*. *Epilepsy Behav Case Rep*. 2014;2(1):80–5.
24. Cimini A, Ricci M, Gigliotti PE, Pugliese L, Chiaravalloti A, Danieli R, et al. Medical imaging in the diagnosis of schistosomiasis: A review. *Pathogens*. 2021;10(8).
25. Haman NO, Bello F, Ndome TO, Baboke I, Fogue D, Djientcheu VDP. Spinal cord schistosomiasis in a 6-year-old child with complete recovery after spine surgery and medical treatment: case report and discussion. *Child's Nervous System*. 2024 Feb 1;40(2):327–33.
26. Del Brutto OH. Parasitic infections of the central nervous system. In: *CNS Infections: A Clinical Approach: Second Edition*. Springer International Publishing; 2018. p. 181–97.
27. Garcia HH. Parasitic Infections of the Nervous System. Vol. 27, *CONTINUUM Lifelong Learning in Neurology*. Lippincott Williams and Wilkins; 2021. p. 943–62.
28. Wen SCH, Anderson R, Ryan MM, Kumbla S, Wray A, Steer A. Pediatric neuroschistosomiasis: A case report and review of the literature. Vol. 8, *Journal of the Pediatric Infectious Diseases Society*. Oxford University Press; 2019. p. 489–91.
29. Halili S, Grant JR, Pilote N, Gordon CA, Williams SA. Development of a novel real-time polymerase chain reaction assay for the sensitive detection of *Schistosoma japonicum* in human stool. *PLoS Negl Trop Dis*. 2021;15(10).
30. Ferrari TCA, Albricker ACL, Gonçalves IM, Freire CMV. Schistosome-Associated Pulmonary Arterial Hypertension: A Review Emphasizing Pathogenesis. *Front Cardiovasc Med*. 2021;8(724254):1.
31. Alanazi RF, Al Karawi M, Almalki A, Sufiani F, Al Karawi S. Schistosomiasis Involving the Central Nervous System: Case Report of a Rare Complication. *Case Rep Surg*. 2023 Dec 12;2023:1–5.
32. Suthiphosuwat S, Lin A, Gao AF, Munoz DG, Spears J, Bharatha A. Delayed presentation of cerebral schistosomiasis presenting as a tumor-like brain lesion. *Neuroradiology Journal*. 2018;31(4):395–8.
33. de Wilton A, Aggarwal D, Jäger HR, Manji H, Chiodini PL. Delayed diagnosis of spinal cord schistosomiasis in a non-endemic country: A tertiary referral centre experience. *PLoS Negl Trop Dis*. 2021;15(2).
34. Wang XY, He J, Juma S, Kabole F, Guo J gang, Dai JR, et al. Efficacy of China-made praziquantel for treatment of *Schistosoma haematobium* in Africa: A randomized controlled trial. *PLoS Negl Trop Dis*. 2019;13(4).
35. Abou-El-Naga IF, Amer EI, Boulos LM, El-Faham MH, Abou Seada NM, Younis SS. Biological and proteomic studies of *Schistosoma mansoni* with decreased sensitivity to praziquantel. *Comp Immunol Microbiol Infect Dis*. 2019;66:1–13.

36. Ahmed MMZE, Osman HHM, Mohamed AHA, Ginawi A. Surgical management outcome of cerebral schistosomiasis: a case report and review of the literature. *J Med Case Rep.* 2021;15(1).
37. Chauvin A, Ghazali A, Le Jeunne C, Plaisance P, Szwebel TA, Costedoat-Chalumeau N, et al. Acute paraplegia due to schistosomiasis: an uncommon cause in developed countries. *J Neurovirol.* 2019;25(3):434–7.
38. Torres-Vitolasid CA, Trienekens SCM, Zaadnoordijk W, Gouvras AN. Behaviour change interventions for the control and elimination of schistosomiasis: A systematic review of evidence from low- and middle-income countries. *PLoS Negl Trop Dis.* 2023;17(5).

Blood trematodes: Schistosomiasis in Central Nervous System

ORIGINALITY REPORT

11%

SIMILARITY INDEX

5%

INTERNET SOURCES

9%

PUBLICATIONS

3%

STUDENT PAPERS

PRIMARY SOURCES

- 1

Mohamud A Verjee. "
Schistosomiasis: Still a Cause of Significant
Morbidity and Mortality
", Research and Reports in Tropical Medicine,
2020
Publication

2%
- 2

"Challenges in Infectious Diseases", Springer
Science and Business Media LLC, 2013
Publication

1%
- 3

Joseph Opare, Tei Hervie, Ernest Mensah,
Charles Brown-Davies et al. "Schistosomiasis
in Ghana from baseline to now: the impact of
fifteen years of interventions", Frontiers in
Public Health, 2025
Publication

1%
- 4

Submitted to unikal
Student Paper

1%
- 5

Xiaodong Yang, Xuefei Yang, Zhiyong Hou,
Minghui Li et al. "Efficient removal of aqueous
ciprofloxacin antibiotic by ZnO/CuO-bentonite
composites synthesized via carbon-bed
pyrolysis of bentonite and metal co-
precipitation", Science of The Total
Environment, 2024
Publication

1%
- 6

www.coursehero.com
Internet Source

1%

7	Applied Anatomy of the Back, 1985. Publication	1 %
8	seimc.org Internet Source	1 %
9	apps.who.int Internet Source	1 %
10	Submitted to National University of Ireland, Galway Student Paper	<1 %
11	Anushree Bansal, Joselv Eullaran Albano, Dheeraj Jayakumar. "Neuroschistosomiasis presenting as recurrent seizures: A case report", Surgical Neurology International, 2025 Publication	<1 %
12	en.wikipedia.org Internet Source	<1 %
13	opencivilengineeringjournal.com Internet Source	<1 %
14	surgicalneurologyint.com Internet Source	<1 %
15	Rickenbacher, Josef, Alex M. Landolt, Karl Theiler, Heinrich Scheier, Jean Siegfried, Franz J. Wagenhäuser, R. R. Wilson, and D. P. Winstanley. "Vertebral Region", Applied Anatomy of the Back, 1985. Publication	<1 %
16	Thiago Augusto Vasconcelos Miranda, Kazuhiro Tsuchiya, Leandro Tavares Lucato. "Imaging of Central Nervous System Parasitic Infections", Neuroimaging Clinics of North America, 2023 Publication	<1 %

17

medbox.org

Internet Source

<1 %

18

pmc.ncbi.nlm.nih.gov

Internet Source

<1 %

Exclude quotes On

Exclude matches < 10 words

Exclude bibliography On

Blood trematodes: Schistosomiasis in Central Nervous System

GRADEMARK REPORT

FINAL GRADE

GENERAL COMMENTS

/0

PAGE 1

PAGE 2

PAGE 3

PAGE 4

PAGE 5

PAGE 6

PAGE 7

PAGE 8

PAGE 9

PAGE 10

PAGE 11

PAGE 12